Dilon Technologies Molecular Breast Imaging Offers A Clear Look Beyond Mammography, MRI and Ultrasound Studies to be Presented at the RSNA

NEWPORT NEWS, Va., Dec. 1 /PRNewswire/ -- Dilon Technologies, Inc., a leader in molecular breast imaging, announced today that leading physicians will present studies at the annual meeting of the Radiological Society of North America (RSNA) that demonstrate Breast Specific Gamma Imaging (BSGI) goes beyond mammography, MRI and ultrasound, and is emerging as a cost-effective adjunct imaging modality for breast cancer diagnostics. Researchers are advancing the early detection of breast cancer, especially in difficult-to-diagnose patients, using this molecular breast imaging technique.

"This research will demonstrate compelling evidence that BSGI is paving the way to the effective diagnosis of breast cancer," said Bob Moussa, President and CEO of Dilon Technologies. "BSGI provides critical diagnostic information for physicians to diagnose and treat patients. In these cases you will see BSGI performing as well as, if not better than, mammography, MRI and ultrasound."

BSGI is an adjunctive molecular breast imaging technique to mammography that can see lesions independent of tissue density and discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image. The Dilon 6800 Gamma Camera is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI.

About Dilon Technologies

Dilon Technologies, Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.

About the RSNA

The 94th Scientific Assembly and Annual Meeting for the Radiological Society of North America (RSNA) will be held November 30 through December 5, 2008, at McCormick Place Convention Center in Chicago. More than 60,000 medical and science professionals from around the globe are expected to attend the world's largest medical meeting. For more information, visit http://www.rsna.org.

CONTACT: Nancy F. Morter of Dilon Technologies, Inc., +1-757-269-4910,
ext. 302, Cell, +1-757-589-3914, nfmorter@dilon.com

Web site: http://www.dilon.com/